Increased complement activation in human type 1 diabetes pancreata

Patrick Rowe, Clive Wasserfall, Byron Croker, Martha Campbell-Thompson, Alberto Pugliese, Mark Atkinson, Desmond Schatz

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective - Evidence supporting an association between complement (C) and type 1 diabetes (T1D) includes the identification of C-fixing islet cell autoantibodies in T1D sera and genetic associations with the major histocompatibility complex III C4 region on chromosome 6. Therefore, we investigated whether C activation was present in pancreata from those with or at increased risk (positive for T1D associated autoantibodies) for T1D. Research Design and Methods - Immunohistochemical techniques were used to measure the C degradation product C4d in organ donor pancreata frompatients with T1D and type 2 diabetes and autoantibody-positive and autoantibody-negative subjects. Results - Median C4d antigen density differed across the groups (P < 0.0001) and was highest in patients with T1D. C4d immunostaining localized to the blood vessel endothelium and extracellular matrix surrounding blood vessels and exocrine ducts. Receiver operating characteristic analysis resulted in 81.8% sensitivity and 94.4% specificity for C4d staining. Conclusions - These data suggest that C activation is occurring within pancreata from patients with T1D and C4d may be a biomarker for T1D.

Original languageEnglish
Pages (from-to)3815-3817
Number of pages3
JournalDiabetes Care
Volume36
Issue number11
DOIs
StatePublished - Nov 1 2013

Fingerprint

Complement Activation
Type 1 Diabetes Mellitus
Pancreas
Autoantibodies
Type 2 Diabetes Mellitus
Blood Vessels
Complement C1
Chromosomes, Human, Pair 6
Electron Transport Complex III
Major Histocompatibility Complex
Islets of Langerhans
ROC Curve
Endothelium
Extracellular Matrix
Research Design
Biomarkers
Tissue Donors
Staining and Labeling
Antigens
Sensitivity and Specificity

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Rowe, P., Wasserfall, C., Croker, B., Campbell-Thompson, M., Pugliese, A., Atkinson, M., & Schatz, D. (2013). Increased complement activation in human type 1 diabetes pancreata. Diabetes Care, 36(11), 3815-3817. https://doi.org/10.2337/dc13-0203

Increased complement activation in human type 1 diabetes pancreata. / Rowe, Patrick; Wasserfall, Clive; Croker, Byron; Campbell-Thompson, Martha; Pugliese, Alberto; Atkinson, Mark; Schatz, Desmond.

In: Diabetes Care, Vol. 36, No. 11, 01.11.2013, p. 3815-3817.

Research output: Contribution to journalArticle

Rowe, P, Wasserfall, C, Croker, B, Campbell-Thompson, M, Pugliese, A, Atkinson, M & Schatz, D 2013, 'Increased complement activation in human type 1 diabetes pancreata', Diabetes Care, vol. 36, no. 11, pp. 3815-3817. https://doi.org/10.2337/dc13-0203
Rowe P, Wasserfall C, Croker B, Campbell-Thompson M, Pugliese A, Atkinson M et al. Increased complement activation in human type 1 diabetes pancreata. Diabetes Care. 2013 Nov 1;36(11):3815-3817. https://doi.org/10.2337/dc13-0203
Rowe, Patrick ; Wasserfall, Clive ; Croker, Byron ; Campbell-Thompson, Martha ; Pugliese, Alberto ; Atkinson, Mark ; Schatz, Desmond. / Increased complement activation in human type 1 diabetes pancreata. In: Diabetes Care. 2013 ; Vol. 36, No. 11. pp. 3815-3817.
@article{6d1f6301820b4e3d9a05d229bac285c6,
title = "Increased complement activation in human type 1 diabetes pancreata",
abstract = "Objective - Evidence supporting an association between complement (C) and type 1 diabetes (T1D) includes the identification of C-fixing islet cell autoantibodies in T1D sera and genetic associations with the major histocompatibility complex III C4 region on chromosome 6. Therefore, we investigated whether C activation was present in pancreata from those with or at increased risk (positive for T1D associated autoantibodies) for T1D. Research Design and Methods - Immunohistochemical techniques were used to measure the C degradation product C4d in organ donor pancreata frompatients with T1D and type 2 diabetes and autoantibody-positive and autoantibody-negative subjects. Results - Median C4d antigen density differed across the groups (P < 0.0001) and was highest in patients with T1D. C4d immunostaining localized to the blood vessel endothelium and extracellular matrix surrounding blood vessels and exocrine ducts. Receiver operating characteristic analysis resulted in 81.8{\%} sensitivity and 94.4{\%} specificity for C4d staining. Conclusions - These data suggest that C activation is occurring within pancreata from patients with T1D and C4d may be a biomarker for T1D.",
author = "Patrick Rowe and Clive Wasserfall and Byron Croker and Martha Campbell-Thompson and Alberto Pugliese and Mark Atkinson and Desmond Schatz",
year = "2013",
month = "11",
day = "1",
doi = "10.2337/dc13-0203",
language = "English",
volume = "36",
pages = "3815--3817",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Increased complement activation in human type 1 diabetes pancreata

AU - Rowe, Patrick

AU - Wasserfall, Clive

AU - Croker, Byron

AU - Campbell-Thompson, Martha

AU - Pugliese, Alberto

AU - Atkinson, Mark

AU - Schatz, Desmond

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Objective - Evidence supporting an association between complement (C) and type 1 diabetes (T1D) includes the identification of C-fixing islet cell autoantibodies in T1D sera and genetic associations with the major histocompatibility complex III C4 region on chromosome 6. Therefore, we investigated whether C activation was present in pancreata from those with or at increased risk (positive for T1D associated autoantibodies) for T1D. Research Design and Methods - Immunohistochemical techniques were used to measure the C degradation product C4d in organ donor pancreata frompatients with T1D and type 2 diabetes and autoantibody-positive and autoantibody-negative subjects. Results - Median C4d antigen density differed across the groups (P < 0.0001) and was highest in patients with T1D. C4d immunostaining localized to the blood vessel endothelium and extracellular matrix surrounding blood vessels and exocrine ducts. Receiver operating characteristic analysis resulted in 81.8% sensitivity and 94.4% specificity for C4d staining. Conclusions - These data suggest that C activation is occurring within pancreata from patients with T1D and C4d may be a biomarker for T1D.

AB - Objective - Evidence supporting an association between complement (C) and type 1 diabetes (T1D) includes the identification of C-fixing islet cell autoantibodies in T1D sera and genetic associations with the major histocompatibility complex III C4 region on chromosome 6. Therefore, we investigated whether C activation was present in pancreata from those with or at increased risk (positive for T1D associated autoantibodies) for T1D. Research Design and Methods - Immunohistochemical techniques were used to measure the C degradation product C4d in organ donor pancreata frompatients with T1D and type 2 diabetes and autoantibody-positive and autoantibody-negative subjects. Results - Median C4d antigen density differed across the groups (P < 0.0001) and was highest in patients with T1D. C4d immunostaining localized to the blood vessel endothelium and extracellular matrix surrounding blood vessels and exocrine ducts. Receiver operating characteristic analysis resulted in 81.8% sensitivity and 94.4% specificity for C4d staining. Conclusions - These data suggest that C activation is occurring within pancreata from patients with T1D and C4d may be a biomarker for T1D.

UR - http://www.scopus.com/inward/record.url?scp=84891872943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891872943&partnerID=8YFLogxK

U2 - 10.2337/dc13-0203

DO - 10.2337/dc13-0203

M3 - Article

VL - 36

SP - 3815

EP - 3817

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -